A leaf extract from the makopa leaf, a common fixture in many Filipino backyards, killed human breast cancer cells in laboratory tests while largely sparing healthy cells, according to a Philippine study that researchers say could help guide future drug development.
Scientists from the University of the Philippines Manila and Virgen Milagrosa University Foundation reported that a flavonoid-rich extract from makopa leaves induced apoptosis, or programmed cell death, in MCF-7 breast cancer cells, a laboratory cell line widely used in cancer research.
The study, published in Acta Medica Philippina, found that the extract fragmented the cancer cells’ DNA and activated caspase-3, an enzyme involved in programmed cell death. At a concentration of 7.2 micrograms per milliliter, the extract reduced the surviving cancer cell population by half while showing no significant toxicity to normal human breast epithelial cells used for comparison.
Lead researcher Gerard Q. De Guzman of the University of the Philippines Manila’s Department of Pharmacology and Toxicology said the findings underscore the potential of Philippine native plants in the search for new cancer treatments.
“This finding highlights the potential of our indigenous plants to contribute to the search for safer and more accessible treatment options,” De Guzman said. “But we must emphasize this is only the first step.”
Makopa (Syzygium samarangense) is widely grown across the Philippines for its crisp, bell-shaped fruit. For the study, researchers collected leaves in San Carlos City, Pangasinan, then processed them through controlled methanol extraction and laboratory fractionation. The extract used in the research is not comparable to homemade preparations such as teas or juices.
“Researchers said breast cancer ranks as the most commonly diagnosed cancer among women in the Philippines, making the search for affordable and effective therapies a continuing public health priority.
In addition to its anticancer activity, the makopa leaf extract demonstrated antioxidant activity comparable to vitamin C in laboratory tests.
Researchers cautioned that the findings are limited to experiments conducted on cultured cells and should not be interpreted as evidence that makopa can treat or prevent breast cancer in people. They have not tested the extract in animals or humans, and they still do not know its safety, effectiveness, or how it behaves inside the body.
“Many promising plant extracts never make it beyond the petri dish,” said co-author Shiela D.V. Miranda of Virgen Milagrosa University Foundation. “We still need to isolate the specific compounds responsible, understand their mechanisms better, and test them in more complex models.”
The research adds to a growing body of studies examining medicinal compounds in Southeast Asian plants. Researchers said makopa and related Syzygium species have long been part in traditional medicine. This study, they said, is one of the first detailed investigations of flavonoid‑rich makopa leaf extracts against human breast cancer cells.
The next stage of the research will focus on identifying and purifying the most active compounds before conducting preclinical animal studies to evaluate toxicity, dosage and bioavailability.
The researchers said the findings illustrate both the pharmaceutical potential of native Philippine plants and the extensive testing required before any laboratory discovery could become a safe and effective treatment for patients.
About The Author
